TESARO and MD Anderson Announce Immuno-Oncology Collaboration and Exclusive License
Tuesday, March 29, 2016 - 07:30
in Mathematics & Economics
TESARO, Inc., an oncology focused biopharmaceutical company, and the Institute for Applied Cancer Science at The University of Texas MD Anderson Cancer Center today announced an exclusive collaboration to discover and develop small molecule product candidates against undisclosed immuno-oncology targets.